Edition:
United States

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

10.29USD
14 Dec 2017
Change (% chg)

$-0.16 (-1.53%)
Prev Close
$10.45
Open
$10.45
Day's High
$11.14
Day's Low
$10.05
Volume
6,430
Avg. Vol
7,377
52-wk High
$16.59
52-wk Low
$7.95

Chart for

About

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress

* Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS Congress

Oct 04 2017

BRIEF-Summit Therapeutics announces pricing of public offering $12.00 per ADS

* Summit Therapeutics announces pricing of public offering of 1,459,000 American Depositary Shares

Sep 13 2017

BRIEF-Summit Therapeutics announces proposed public offering of $15 mln of American Depositary shares

* Summit Therapeutics announces proposed public offering of $15.0 million of American Depositary shares Source text for Eikon: Further company coverage:

Sep 13 2017

BRIEF-Summit awarded BARDA contract worth up to $62 million

* Summit awarded BARDA contract worth up to $62 million to support the development of ridinilazole for the treatment of C. difficile infection

Sep 11 2017

BRIEF-Summit announces positive top-line data from an exploratory phase 2 supporting Ridinilazole

* Summit announces positive top-line data from an exploratory phase 2 clinical trial supporting Ridinilazole as a highly selective antibiotic for the treatment of CDI

Sep 05 2017

BRIEF-Summit Therapeutics reports financial results for Q2 ended July 31 2017

* Summit Therapeutics reports financial results for the second quarter and half year ended July 31 2017 and operational progress

Aug 31 2017

Earnings vs. Estimates